CD274 and head and neck squamous cell carcinoma: Combining durvalumab (MEDI4736, PD-L1 inhibitor) with danvatirsen or AZD5069 (CXCR2 inhibitor) (NCT02499328) in patients with advanced solid malignancies and HNSCC improved anticancer activity as compared to PD-L1 monotherapy [81].